Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > new investor read Granhamb and negative friends want our VPT
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by theNormon Nov 09, 2022 2:53am
121 Views
Post# 35084241

RE:RE:new investor read Granhamb and negative friends want our VPT

RE:RE:new investor read Granhamb and negative friends want our VPT
So Graham you admit you have no shares and don't want "cheapies". You ignore VMS being part of GEHC Edison programs Vivid 4D Echopac and the sales potential of their 40% of global imaging market? You ignore the estimated 7.5 million VPT has in cash estimates Oct 27 news to last 12 to 18 months with significant sales expected b4 then? Please save yourself from further embarrassment and stop your attempts to bash VPT. NICE is under internal review and will get published again. 4 sales will soon become 40+ and GEHC will most probably be the one to buyout VPT at the CEO George Adam's projected 2 billion USD valuation in 2023
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities